Trial Profile
A Randomized, Double-blind Study of the Effect of Tocilizumab on Reduction in Signs and Symptoms in Patients With Moderate to Severe Active Rheumatoid Arthritis and Inadequate Response to DMARD Therapy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Tocilizumab (Primary) ; Disease-modifying antirheumatics; Methotrexate
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms TOWARD
- Sponsors Roche
- 26 Aug 2020 Results of a pooled analysis from twelve phase 3 and 4 clinical trials: ACT-RAY, ACT-STAR, ACT-SURE, ADACTA, AMBITION, BREVACTA, COMP-ACT, LITHE, OPTION, ROSE, SUMMACTA and TOWARD assessing predictors of response, including demographics, disease characteristics at baseline published in the Rheumatology
- 06 Jun 2020 Results of pooled analysis from seven studies (OPTION, RADIATE, TOWARD, LITHE, ACT-RAY, ADACTA and BREVACTA) presented at the 21st Annual Congress of the European League Against Rheumatism.
- 06 Jun 2020 Results of pooled analysis from three phase III studies (OPTION, TOWARD and LITHE) presented at the 21st Annual Congress of the European League Against Rheumatism